Anti-4-1bb nanobodies
US-2024383993-A1 · Nov 21, 2024 · US
Gitr antagonists and methods of using the same
US2024158525A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2024158525-A1 |
| Application number | US-202318531856-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 7, 2023 |
| Priority date | Feb 2, 2021 |
| Publication date | May 16, 2024 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.
First claim
Opening claim text (preview).
1 - 19 . (canceled) 20 . A compound having the formula: X-L-M or M-L-X, wherein X is an antibody Fab fragment or an antibody Fab′ fragment that binds human GITR (SEQ ID NO: 20) and comprises 1) a heavy chain variable region (VH) as shown in SEQ ID NO: 8 or SEQ ID NO: 9, and 2) a light chain variable region (VL) as shown in SEQ ID NO: 10; wherein M is a VHH moiety that binds to human serum albumin; and wherein L (if present) is a linker. 21 . The compound of claim 20 , wherein the VHH moiety is fused to the C-terminus of the heavy chain first constant domain (CH1) of the Fab fragment or an antibody Fab′ fragment via L, wherein the fusion comprises SEQ ID NO: 14 or SEQ ID NO: 15; and wherein the light chain (LC) comprising SEQ ID NO: 16. 22 . A method of treating atopic dermatitis (AtD), arthritis, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease (CD) or ulcerative colitis (UC) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 20 . 23 . A method of treating AtD, arthritis, RA, IBD, CD or UC in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound of claim 21 .
Assignees
Inventors
Classifications
- C07K16/2878Primary
against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression · CPC title
Complementarity determining region [CDR] · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2024158525A1 cover?
- The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.
- Who is the assignee on this patent?
- Lilly Co Eli
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2878. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu May 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).